Loading
Cisplatin for injection / NSCLC (advanced Non Small Cell Lung Cancer) / EGFR · Phase 3 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospective Phase 3 RCT comparing firmonertinib to platinum-based chemotherapy in treatment-naïve patients with EGFR PaCC or EGFR l861q mutant NSCLC. The registry record describes the planned study only; no efficacy or safety results have been posted.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. EGFR, NSCLC (Advanced Non-small Cell Lung Cancer); age from 18 Years. Intervention: Firmonertinib. Compared with: chemotherapy — Active Comparator. n = 300. 2 sites: China.
This is a prospective Phase 3 RCT comparing firmonertinib to platinum-based chemotherapy in treatment-naïve patients with EGFR PaCC or EGFR l861q mutant NSCLC. The registry record describes the planned study only; no efficacy or safety results have been posted.
No efficacy or safety results are posted in this registry record
The source did not state who this applies to in practice.
This is a Phase 3 RCT registration with no posted results; the study is actively recruiting and outcomes are not yet reported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06956001). This is a study registration, not published results. Lead sponsor: Allist Pharmaceuticals, Inc.. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 300 participants (ESTIMATED). Conditions: EGFR, NSCLC (Advanced Non-small Cell Lung Cancer). Interventions: DRUG: Firmonertinib Mesilate Tablets; DRUG: Pemetrexed Disodium for Injection; DRUG: Cisplatin for injection; DRUG: Carboplatin Injection. Primary outcome measures: Progression-free survival (PFS) assessed by the Independent Review Committee (BICR) according to RECIST v1.1. , Up to 3 years. Brief summary: This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.